10times
22 Jun 2021 • 

ALS Biomarkers in Drug Development

AboutSpeakersExhibitorsReviewsPhotos

Official Links

Estimated Turnout

upto 100
Delegates

Editions

Jun 2021

Frequency

Newly Listed
Claim event to edit details

Nerve cells break down and reduce functionality in the muscles they supply. The first part of the webinar will provide an overview of ALS biomarkers, .. Read more both fluid-based (blood, urine and cerebrospinal fluid) and non-fluid based (electrophysiology and PET/imaging). From there, the panel will focus on individual types of ALS biomarkers, discussing which are most helpful in terms of the science of the disease, including identification and diagnosis. In addition, the group will talk about the application of ALS biomarkers in drug development, addressing which are most useful and best translate in clinical research and in assessing a drug’s effect on the disease. The non-fluid-based ALS biomarkers will include electrophysiology and PET/imaging. Biomarkers derived from blood, urine and cerebrospinal fluid provide the necessary biological information for the diagnosis and can be used as an indicator of disease progress and severity. Finally, the panel will make specific and even controversial recommendations regarding ALS biomarkers in clinical trials.

  • Share your Experience
  • Organizer
LogoRequest a Booth

Xtalks

Canada463 Total Events / 19 Upcoming Events

More Events From The Organizer

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results